Opposite Effects of mGluR1a and mGluR5 Activation on Nucleus Accumbens Medium Spiny Neuron Dendritic Spine Density.
Gross KS, Brandner DD, Martinez LA, Olive MF, Meisel RL, Mermelstein PG. · 2016
Read Opposite Effects of mGluR1a and mGluR5 Activation on Nucleus Accumbens Medium Spiny Neuron Dendritic Spine Density. by Gross KS, Brandner DD, Martinez LA, Olive MF, Meisel RL, Mermelstein PG. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5019418.txt.
Introduction
Kellie S. Gross and five co-authors compare two related receptors in the brain's reward hub, in PLoS ONE in 2016. The receptors, mGluR1a and mGluR5, both answer the signal chemical glutamate and shape how nerve cells change. Drugs aimed at them are being weighed for addiction care, so knowing each one's separate effect matters. The team boosted each receptor in turn and counted dendritic spines, the tiny knobs where nerve cells receive signals, in the nucleus accumbens.
The two boosts pulled in opposite directions. Turning up mGluR5 lowered spine counts in both parts of the nucleus accumbens, while turning up mGluR1a raised them. Neither changed the dorsal striatum nearby. Injecting an mGluR5 activator straight into the nucleus copied the drop. The findings warn that sister receptors in one drug family can reshape brain wiring in opposing ways.
Catalog record
| CREATOR | Gross KS, Brandner DD, Martinez LA, Olive MF, Meisel RL, Mermelstein PG. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Opposite Effects of mGluR1a and mGluR5 Activation on Nucleus Accumbens Medium Spiny Neuron Dendritic Spine Density By Kellie S. Gross, Dieter D. Brandner, Luis A. Martinez, M. Foster Olive, Robert L. Meisel, Paul G. Mermelstein, Juan M Dominguez Published in: PLoS ONE DOI: 10.1371/journal.pone.0162755 ABSTRACT The group I metabotropic glutamate receptors (mGluR1a and mGluR5) are important modulators of neuronal structure and function. Although these receptors share common signaling pathways, they are capable of having distinct effects on cellular plasticity. We investigated the individual effects of mGluR1a or mGluR5 activation on dendritic spine density in medium spiny neurons in the nucleus accumbens (NAc), which has become relevant with the potential use of group I mGluR based therapeutics in the treatment of drug addiction. We found that systemic administration of mGluR subtype-specific positive allosteric modulators had opposite effects on dendritic spine densities. Specifically, mGluR5 positive modulation decreased dendritic spine densities in the NAc shell and core, but was without effect in the dorsal striatum, whereas increased spine densities in the NAc were observed with mGluR1a positive modulation. Additionally, direct activation of mGluR5 via CHPG administration into the NAc also decreased the density of dendritic spines. These data provide insight on the ability of group I mGluRs to induce structural plasticity in the NAc and demonstrate that the group I mGluRs are capable of producing not just distinct, but opposing, effects on dendritic spine density. INTRODUCTION The group I metabotropic glutamate receptors (mGluRs), mGluR1a and mGluR5, are important modulators of neural signaling and plasticity. Located primarily on post-synaptic structures, they couple predominately to Gq G-proteins to activate a number of downstream signaling pathways that have both acute and long-term effects on neuronal excitability [1]. Given the variety of effects these receptors can have on neural plasticity and their wide expression throughout the brain, group I mGluRs are involved in virtually all nervous system functions and play important roles in a number of disease states, including drug addiction [2]. One way group I mGluRs may influence function is by regulating neural structure. In hippocampal neurons, for example, activating group I mGluRs with the pan-specific orthosteric agonist (S)-3,5-Dihydroxyphenylglycine (DHPG) leads to elongation of dendritic spines and decreases in spine density, suggesting a weakening and loss of synaptic connections [3–5]. Correlated with these structural changes, DHPG induces functional plasticity, leading to the development of long-term depression in both hippocampal pyramidal neurons and many other cell types [2]. This effect of group I mGluR activation on dendritic spine plasticity may have an important biological role as a mechanism of the normal activity-dependent synaptic remodeling and refinement that occurs as a result of learning or other experiences [5]. Additionally, group I mGluR regulation of spine structure has been linked to certain disease states. As examples, dysregulated mGluR5 signaling underlies spine abnormalities in models of Fragile X syndrome [6], and spine loss seen in models of Alzheimer’s disease [7]. Although the two group I mGluRs are closely related and couple to many of the same downstream signaling pathways, accumulating evidence demonstrates that mGluR1a and mGluR5 can also have distinct functions [8]. This observation highlights the importance of separately evaluating the influences of mGluR1a versus mGluR5, especially in regions where they are co-expressed, on neuronal function. Until now, the majority of studies looking at the effects of group I mGluRs on structural plasticity have not explored potential differences between these receptor subtypes. However, recent work examining estrogen effects on dendritic spine densities in the female nucleus accumbens (NAc) have provided indirect evidence of opposing functions of mGluR1a and mGluR5 in regulating structural changes. In the NAc core (NAcC), estradiol decreases spine density through an mGluR5 dependent mechanism [9]. Conversely, in the NAc shell (NAcSh), estradiol increases spine density via mGluR1a, an increase similar to what has been observed in the hippocampus and hypothalamus [9–11]. The possibility that the two group I mGluRs are having opposing effects on structural plasticity in the NAc is particularly intriguing as group I mGluR signaling in this region is thought to be heavily involved in the pathophysiology of addiction, and therapeutics are being developed for addiction that target the mGluR system [12]. With only ancillary evidence that mGluR1a and mGluR5 can have opposing effects on dendritic spine densities in the NAc, we sought to determine the effects of independent activation of these individual receptors on both spine density and morphology. Experiments were performed in ovariectomized female rats to eliminate estrogen as a source of activation of group I mGluR signaling [9]. Because of the high specificity and therapeutic potential of mGluR positive allosteric modulators (PAMs), we first looked at the effects of systemic treatment with an mGluR5 or an mGluR1 PAM. Direct infusion of a specific mGluR5 agonist into the NAc was also performed to determine whether local activation of mGluRs was sufficient to alter dendritic spines. METHODS Animals Female Sprague-Dawley rats (175–200 g) were ovariectomized by Envigo Laboratories (Indianapolis, IN) and arrived fully recovered from the procedure and in good health. Animals were pair housed and kept under a 14:10 light-dark cycle with lights on at 6 a.m. Food and water were available ad libitum. Animals were allowed to habituate for five days prior to experimentation. All animal procedures were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee at the University of Minnesota (Animal Welfare Assurance Number A3456-01). Drugs 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) and (RS)-2-Chloro-5-hydroxyphenylglycine sodium salt (CHPG) were obtained from Tocris Bioscience (Minneapolis, MN). CDPPB was suspended in 0.5% methyl cellulose (w/v in deionized water, Sigma-Aldrich, St. Louis, MO). CHPG was dissolved in sterile saline. 9H-Xanthene-9-carboxylic acid (4-trifluoromethyl-oxazol-2-yl)-amide (SYN119) was synthesized by EAG Laboratories (Sunnyvale, CA) and was suspended in 20% 2-hydroxypropyl-β-cyclodextrin (w/v in deionized water, Sigma-Aldrich). For systemic treatments, CDPPB (5–10 mg/kg), SYN119 (10 mg/kg), or their corresponding vehicles were administered intraperitoneally (i.p.) at a volume of 2 ml/kg. For site-specific drug administration, CHPG (10 μg/0.5 μl/side) or an equivalent volume of vehicle was infused directly into the NAc. For all experiments, animals were sacrificed 24 hours after drug administration and tissue was processed for dendritic spine analysis. Surgical microinjection procedure Animals were anesthetized with a 2.5–4% isoflurane (Piramal Critical Care, Bethlehem, PA)/oxygen mixture and placed in a stereotaxic apparatus. Drug or vehicle was injected bilaterally via a Hamilton microinjection syringe at the following coordinates targeting the core-shell border: AP: +1.80 mm from bregma, ML: ±1.50 mm from bregma, DV: -6.20 mm from dura. Infusions of 0.5 μl were given manually over the course of 2.5 minutes. The injection needle was then left in place for an additional 2.5 minutes to allow for diffusion of the drug away from the needle tip. Animals were given a subcutaneous injection of 2.5 mg/kg ketoprofen 20 minutes prior to surgery and every 12 hours after surgery to induce analgesia and a subcutaneous injection of 10 mg/kg Baytril at the time of surgery to prevent infection. Immediately following the surgery, animals were monitored until they recovered ambulatory posture. Afterwards, animals were observed for eating, drinking, and or the display of any discomfort. None of the animals exhibited any symptoms of problems. Location of the injection site was verified following